{
    "nct_id": "NCT06678659",
    "official_title": "A Phase 1 / 2, Open-Label Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer (DAHLIA)",
    "inclusion_criteria": "* 18 years or older Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy.\n\nECOG performance status â‰¤ 1 Measurable disease at baseline per RECIST 1.1 / Lugano criteria and documented by computed CT and / or MRI\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received treatment with another RBM39 degrader Clinically significant gastrointestinal (GI) or GI malabsorption",
    "miscellaneous_criteria": ""
}